Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
grade B 15.33 4.93% 0.72
REPL closed up 4.93 percent on Wednesday, April 24, 2019, on 25 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical REPL trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 50 DMA Bullish 4.93%
MACD Bullish Centerline Cross Bullish 4.93%
Inside Day Range Contraction 4.93%
Wide Bands Range Expansion 4.93%
Fell Below 50 DMA Bearish 12.06%
MACD Bearish Centerline Cross Bearish 12.06%
Wide Bands Range Expansion 12.06%
Oversold Stochastic Weakness 12.06%

Older signals for REPL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Virotherapy Experimental Cancer Treatments Transgene Sa
Is REPL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 14 Replimune Group reports Q3 results
Feb 14 Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
Feb 11 Microcaps dominate midday movers
Feb 11 NuVasive and OHR Pharmaceutical among healthcare gainers; Celldex Therapeutics leads the losers
Feb 7 Replimune to Present at Two Upcoming Investor Conferences
Jan 10 Replimune Group (REPL) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 3 Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
Dec 28 Healthcare & Tech dominate midday movers
Dec 28 OPKO Health and Prana Biotechnology among healthcare gainers; Novus Therapeutics among losers
Dec 27 Microcaps mostly among midday movers
See more REPL news...
Indicators
Indicator Value
52 Week High 23.55
52 Week Low 8.88
Average Volume 106,065
200-Day Moving Average 0.0
50-Day Moving Average 13.9212
20-Day Moving Average 14.9815
10-Day Moving Average 14.239
Average True Range 1.4836
ADX 18.65
+DI 20.6693
-DI 15.7214
Chandelier Exit (Long, 3 ATRs ) 13.0892
Chandelier Exit (Short, 3 ATRs ) 16.5208
Upper Bollinger Band 17.3932
Lower Bollinger Band 12.5698
Percent B (%b) 0.57
BandWidth 32.195708
MACD Line 0.0842
MACD Signal Line 0.2119
MACD Histogram -0.1277
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.55
Resistance 3 (R3) 17.35 16.40 17.18
Resistance 2 (R2) 16.40 15.84 16.51 17.06
Resistance 1 (R1) 15.87 15.49 16.14 16.07 16.93
Pivot Point 14.92 14.92 15.06 15.03 14.92
Support 1 (S1) 14.39 14.36 14.66 14.59 13.73
Support 2 (S2) 13.44 14.01 13.55 13.60
Support 3 (S3) 12.91 13.44 13.48
Support 4 (S4) 13.11